Food CPR Registration Rejected in the Philippines: Reading the Notice and Deciding What to Refile

First, identify what you received: deficiency letter, denial, or administrative return

Bottom line: the FDA issues at least three distinct kinds of paper, and treating one as another is the most expensive mistake in this whole process.

Type one is a deficiency or compliance letter. It means the evaluation is not finished. Your file is suspended, waiting for you to cure the listed findings so review can resume. These letters normally carry a response deadline, and missing it usually does not mean you drift to the back of the queue — it means the application is treated as abandoned and closed outright. A deficiency letter is not a rejection. But if you treat it as one and file a fresh application instead, you have paid twice and thrown away whatever queue position you had earned.

Type two is a denial or disapproval. The evaluation has reached a conclusion and the file is no longer pending. These usually cite the specific provision the decision rests on and state whether reconsideration is available or whether a new submission is the only route. This one is final in character; no amount of supplementary paper reopens it by itself.

Type three is an administrative return. The file was bounced during completeness screening and never reached technical evaluation at all — a missing annex, a format mismatch, a payment reference that does not tie out, the wrong application pathway, attachments named in a way the portal does not accept. This looks the most like a rejection and is in fact the easiest to fix, because nobody has yet formed any view about your product. The same internal machinery is documented in more detail on the device side, and the mechanics carry over: see how the FDA actually evaluates a dossier and when it bounces one.

Sorting them is straightforward. Look at the heading, look for a stated response deadline, and look for a citation supporting a final decision. All three get described as rejected in conversation, but the correct action differs completely: type one is answered inside the existing case, type two forces a reconsideration-or-refile decision, and type three is often cured the same day. Until you know which you are holding, do not touch print files, do not push customer delivery dates, and do not pay a new filing fee.

Reading the notice: the five things that actually determine your next move

Bottom line: only five pieces of information in a rejection notice change what you do next. The rest is boilerplate. Extract them in order and you avoid most wasted rework.

1. The case reference and application pathway. This ties to one specific record in the FDA electronic portal. A cure has to be filed inside that same record. Opening a new application typically abandons the original, and the evaluation progress does not travel with you.
2. The response deadline. This is the hardest constraint in the document. Whether it runs from issuance or from receipt, whether extension is available, and what lapsing actually costs — take all of that from the letter itself and from current FDA rules, not from what a colleague remembers happening once.
3. The numbered findings. This is the substance. Break each finding into three questions: which document does it point at, does it ask you to add a document or to change content, and does curing it force changes elsewhere in the file?
4. The cited basis. The provision referenced tells you the nature of the defect — a formal requirement you can simply satisfy, or a substantive one that may force a change in how the product is declared, or in the product itself.
5. The filing channel and format rules. Portal upload or over-the-counter, whether a new fee applies, whether attachment naming and file formats are prescribed. These are unglamorous and they are a leading cause of second returns.

Then do one thing immediately: map every finding to a specific document and page in the dossier you hold, in a written cross-reference table. Evaluators check your response finding by finding, so your reply letter should mirror their numbering, stating what changed and where, rather than a general narrative with a pile of new attachments for someone else to sort.

The step most often skipped is checking whether findings are linked to each other. If the letter says the ingredient list disagrees with the declared formulation, fixing the label is not the end of it — you now have to confirm that the product name, pack size and specification on the test report, the specification sheet and the certificate of origin do not also need to move. The dossier is a chain of mutually corroborating evidence; touch one link and you re-verify the rest. What each document is meant to prove is covered in the documents a food CPR filing actually requires.

Cause group one: labeling and claims, the highest-frequency and most fixable

Bottom line: labeling findings are the single largest slice of food CPR rejections, and also the most controllable slice, because the rules are written down and leave little discretion.

In a rejection context, labeling defects almost always land in one of four buckets: a mandatory particular is missing; the format is wrong (wording, units, placement or orientation do not follow the prescribed form); the label disagrees with the dossier (what is printed does not match the declared formulation, the test report or the specification sheet); or a claim crosses a line (a prohibited or misleading representation, or wording that strays into therapeutic territory).

Separate the first three from the fourth. The first three are artwork problems. They cost you a revision cycle and possibly a reprint or an overlabel run. The fourth can be a positioning problem. Once a claim points at a physiological effect, the product may be pushed toward a stricter pathway, and you may have to revisit whether it should have been declared as a conventional food at all. The claim boundaries on the supplement side are considerably tighter — see how supplements are registered and where the claim red lines sit.

How to write each particular — the full list of mandatory items, the required date format, where allergen information sits, how a foreign-language original label is handled, which representations are prohibited outright — is not covered here, because it is the entire subject of another article. Go straight to mandatory particulars for prepackaged food labels in the Philippines, and for cross-category baseline rules, Philippine product labeling requirements.

One sequencing warning for handling labels after a rejection: get the artwork to a state that passes as a whole before you commit anything to print. The common failure is calling the printer the same afternoon the letter arrives, fixing exactly what was cited, refiling, and then being cited on a second and third particular — with the new print run already obsolete. Re-audit the entire label against the rules, including the parts nobody flagged. The finding you received is usually just the first defect the evaluator noticed, not a certificate of health for everything else.

Cause group two: formulation and technical documents that do not tie out

Bottom line: a technical finding almost always means your evidence does not carry your declaration. It is not a verdict on the product; it is a verdict on the file.

The recurring forms:

• The formulation declaration is incomplete or non-standard. Ingredients are not listed the prescribed way, compound raw materials are not broken down to their components, additives appear under a trade name with no functional class or standard name. The evaluator cannot determine from that whether the substances fall inside permitted use, so a letter goes out.
• An ingredient is not acceptable as used. The formulation contains something prohibited or restricted in the Philippines, or a substance whose permitted scope of use does not match the food category you declared. Permitted lists, conditions of use and limits are whatever current FDA rules say — do not rely on another jurisdiction's positive list. This is one of the most common sources of misjudgment among Chinese exporters.
• Test reports do not match the declaration. Product name, pack size or batch reference on the report differs from the application; or the parameters tested do not cover what the category requires; or the issuing laboratory is not recognised for the purpose.
• Shelf life is asserted but not supported. The label states a date, and the file contains nothing that establishes it.
• A supporting certificate has expired. Free sale certificates, manufacturing licences and system certifications all carry validity periods. After one round of deficiency correspondence, documents that were valid at filing may have lapsed, which then arrives as a fresh finding.

The classic error here is curing only the cited document and never re-checking consistency. Technical files corroborate each other: change the declared formulation and the test parameters may need to expand; commission a new test report and its stated specification has to be realigned with the label and the specification sheet. Laying the whole set side by side for one cross-check is far cheaper than three rounds of correspondence. Which document proves what, and which carry expiry dates, is set out in the food CPR document set.

Cause group three: applicant eligibility and a broken authorisation chain

Bottom line: this group is the expensive one, because it usually cannot be cured with paper. It is cured by changing who is applying, which means starting the substantive work again.

Three typical situations:

One: the applicant is not a licensed entity. A foreign manufacturer or brand owner cannot be the applicant for a Philippine food CPR. The applicant must be a locally established entity holding the appropriate FDA License to Operate. The foreign side either sets up a local entity and obtains that licence itself, or files through an already-licensed local authorised representative or importer, who then becomes the holder of the certificate. This is not a technicality to be worked around; it is the shape of the market access regime.

Two: the licence class does not match the actual activity. An LTO is issued against declared activities — importer, distributor, manufacturer are distinct classes covering different operations. Filing product applications on a licence that does not cover the relevant activity draws an eligibility finding, and there is no cure inside the product application. You have to fix the licence first. What the licence covers is explained in the permits required to import food into the Philippines.

Three: the authorisation chain is broken or inconsistent. Typical defects in the letter of authorisation from the brand owner to the local representative: the scope does not actually cover filing a product registration in the local entity's name; the authorising party's name does not match the name on the free sale certificate; the authorisation has expired; or the notarisation and legalisation form is not accepted. If any link fails, the whole chain is treated as broken.

Before rushing to fix this, make a commercial decision first: the certificate is issued in the name of whichever licensed entity actually files it. If you intend to be in this market for years, having your registration sit under one distributor's licence leaves you badly placed the day you want to change channel partners. If you are testing demand with a first shipment, filing through a licensed partner is the faster route. That is a channel design question rather than a compliance one, and it decides what happens when distributors change — see how to structure distribution in the Philippines. Yixing's product access practice normally settles who owns the certificate, and what happens on a channel switch, before deciding which entity files.

Refile or start over: the test, and three things to do before resubmitting

Bottom line: there is one test. Are you changing how something is described in the dossier, or changing the product or the applicant itself? The first is a cure inside the existing case. The second is a new application in all but name.

Cure and refile fits: a missing document, an expired document that needs replacing, revised label artwork, internal inconsistencies, additional test parameters, an explanation that needs to be expanded. None of these changes the identity of the product or of the applicant, so they are answered finding by finding inside the original case.

A new application is effectively required when: the applicant changes (a different licensed partner, or moving from a partner's licence to your own entity); the product is reclassified (from conventional food to supplement or the reverse); the formulation changes substantively enough that the original declaration no longer describes it; or the wrong product category and pathway were selected.

In between, the letter decides. If what you hold is a final disapproval, then even a light defect usually leaves only two routes: seek reconsideration through whatever mechanism the letter specifies, or file afresh.

Whichever route you take, do these three things before resubmitting:

1. Answer finding by finding. Mirror the evaluator's numbering, state what changed and on which page of which document, and name attachments to match. Do not hand over a stack of files and expect someone else to build the mapping.
2. Run a whole-dossier consistency pass. Product name, pack size, net content, formulation, batch coding convention and shelf life must read identically on the label, the formulation declaration, the test report and the specification sheet. Identically, not approximately.
3. Run an expiry pass. Tabulate the validity end-date of every supporting certificate and confirm none of them lapse during the coming review round.

Finally, the commercial containment. If goods are already in transit or already at port, the compliance position does not improve merely because you are curing the file. Entering the country and being lawfully sellable are two different things, and without the registration the product cannot be placed on the market. The port-side handling is covered in import commodity clearance at the border. The rest of this cluster covers the other angles: sequence and dependencies, the mistakes that cause most filings to fail, and what to do before the certificate expires.